Wall Street's major averages dipped for the week as investors wrestled with tariff twists from the Trump administration. The ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

Consumers are on board, with an estimated 26% of U.S. adults planning to take a weight loss drug in 2025, according to ...

While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...

A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...

Key Takeaways Novo Nordisk cut Wegovy’s price to $499 per month, a 23% decreaseEli Lilly lowered Zepbound’s starter dose to ...

Adults with obesity who have a prescription for Wegovy but do not have insurance coverage for the drug can now purchase the ...

Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...

A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...

The federal government has spent $6.2 billion on research and development for weight-loss drugs. Now, thanks to Big Pharma ...

Novo Nordisk is cutting the cost of its blockbuster weight-loss drug Wegovy in half for U.S. patients paying cash through its direct-to-patient online pharmacy, as competition in the highly lucrative ...

Novo Nordisk is not concerned by the ongoing US trade war and the 25% tariff set to go into effect for pharmaceutical companies next week. CEO Lars Jørgensen told reporters Thurs ...